title: Who's paying for new drugs?
abstract: Direct payment by patients for treatment with drugs still in development is the subject of controversy. The matter goes deeper than it might first appear.
authors.affiliation: Biological Therapy Institute, Franklin, Tennessee 37064.
authors.forename: R K
authors.initials: RK
authors.lastname: Oldham
mesh_terms: D035843:Biomedical Research; D002986:Clinical Trials as Topic / Q000191:economics; D004341:Drug Evaluation / Q000191:economics; D005069:Evaluation Studies as Topic / Q000191:economics*; D035082:Federal Government; D006801:Humans; D035842:Research Subjects; D012109:Research Support as Topic / Q000191:economics*; D036302:Therapeutic Human Experimentation